ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: L02

Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis

Julie J. Paik1, Jemima Albayda2, Eleni Tiniakou3, Andrew Koenig4 and Lisa Christopher-Stine5, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Pfizer Inc, Collegeville, PA, 5Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Date of first publication: October 4, 2018

Keywords: Clinical trials and dermatomyositis, Late-Breaking 2018

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Late-Breaking Abstract Poster Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 9:00AM-11:00AM

Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy that primarily affects the muscle and skin. In refractory disease, it is common to fail 2 or more steroid sparing agents or high dose steroids. This open-label, 12-week proof-of-concept study was conducted to evaluate the efficacy and safety of tofacitinib, a JAK inhibitor, in active, treatment refractory DM.

Methods: 10 subjects were enrolled at one center. Tofacitinib was given as 11mg XR daily. Subjects were washed out of any steroid sparing agent and not allowed more than 20 mg of prednisone daily prior to study entry.  The primary outcome was the proportion of subjects meeting the definition of improvement (DOI) at 12 weeks, defined by the International Myositis Assessment and Clinical Studies (IMACS) as improvement of ≥ 20% in 3 of 6 core set measures (CSM) with no more than 2 worsening by ≥ 25% [(which cannot include the manual muscle testing (MMT)]. The secondary outcome measures were the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), steroid-sparing effect of tofacitinib, safety, and tolerability.

Results: 9 subjects were analyzed because the last subject has not yet completed the study. All subjects failed at least 2 steroid sparing agents or high dose steroids. All 9 subjects met the primary outcome DOI at 12 weeks, with 5 of 9 (56%) demonstrating moderate improvement and 4 of 9 (44.4%) having minimal improvement based on the Total Improvement Score (TIS) of the Myositis Response Criteria. The median TIS was 40 [IQR 32.5, 47.5] indicative of at least moderate improvement. The secondary outcome of the mean change in CDASI activity score from baseline to 12 weeks was statistically significant (28 ± 15.4 (baseline) vs. 9.5 ± 8.5 (12 weeks), p=0.0005) with clear trend in improvement (Figure 1). Chemokine data on CXCL-9/10 also showed a trend toward improvement with treatment but did not show a statistically significant change from baseline (CXCL9, p=0.09; CXCL10, p=0.06) (Figure 2). Myositis autoantibody titers did not show any change in titer after treatment. Six subjects were positive for anti-TIF-1 gamma and 5 of 6 (83%) were moderate responders. Four of 9 (44.4%) were on prednisone 20mg/daily at entry and 3 of 4 (75%) were able to completely taper off all steroids. Tofacitinib was well tolerated without any serious adverse events.

Conclusion: Tofacitinib demonstrated evidence of strong clinical efficacy as measured by a validated myositis response criteria with a corresponding decrease in chemokine levels. A randomized controlled trial should be considered to further assess efficacy in dermatomyositis. 

 


Disclosure: J. J. Paik, None; J. Albayda, None; E. Tiniakou, None; A. Koenig, Pfizer Inc, 1,Pfizer Inc, 3; L. Christopher-Stine, Inova Diagnostics, 7.

To cite this abstract in AMA style:

Paik JJ, Albayda J, Tiniakou E, Koenig A, Christopher-Stine L. Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/study-of-tofacitinib-in-refractory-dermatomyositis-stir-an-open-label-pilot-study-in-refractory-dermatomyositis/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/study-of-tofacitinib-in-refractory-dermatomyositis-stir-an-open-label-pilot-study-in-refractory-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.